Malignant Lymphoma in Patients with Systemic Rheumatic Disease (Rheumatoid Arthritis,Systemic Lupus Erythematosus,Systemic Sclerosis,and Dermatomyositis): A Clinicopathologic Study of 24 Japanese Cases

Abstract

We conducted clinicopathologic and immunohistochemical analyses of the prevalence of Epstein-Barr virus (EBV) among 24 patients with malignant lymphoma complicating systemic rheumatic diseases. (SRD) These 24 patients included 17 with rheumatoid arthritis (RA), 3 with systemic lupus erythematosus (SLE), 2 with systemic sclerosis (SS), and 2 with dermatomyositis (DM). There were 2 men and 22 women ranging in age from 30 to 86 years (mean: 64 years). The interval between the onset of rheumatic disease and that of malignant lymphomas ranged from 3 months to 35 years (mean: 142 months). The use of immunosuppressive drugs before the onset of malignant lymphoma was recorded in 15 patients. Among them, 5 patients received methotrexate (MTX) therapy. Malignant lymphomas were found at extranodal sites in 9 patients, and the disease was in the advanced stage in 17 patients. Histologic and immunohistochemical studies demonstrated that 18 cases (75%) were B-cell lymphoma (RA=12, SLE=2, SS=2, DM=2), 3 (12.5%) were peripheral T-cell lymphoma (RA=3), and 3 (12.5%) were classical Hodgkin lymphoma (RA=2, SLE=1). As in previous reports, there was an increased frequency of diffuse large B-cell lymphoma (50%) in the present series. Moreover, a majority of the diffuse large B-cell lymphomas exhibited activated B-cell phenotype. EBV-encoded small RNAs (Epstein-Barr early region [EBER]-) and/or LMP-1+tumor cells were identified in only 3 cases of classical Hodgkin lymphomas. Our findings suggested EBV-associated lymphoma comprised only a small fraction of all non-Hodgkin's lymphomas in the general SRD patient population.

Keywords

systemic rheumatic disease malignant lymphoma histopathology immunohistochemistry Epstein-Barr virus

Get full access to this article

View all access options for this article.

References

1. Isomaki HA , Hakulinen T , Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma and myeloma in patients with rheumatoid arthritis. J Chron Dis 31:691-696, 1978

2. Leandro MJ , Isenberg DA . Rheumatic disease and malignancy-is there an association? Scand J Rheumatol 30:185-188, 2001

3. Thomas E , Brewster DH , Black RJ , MacFarlane GJ . Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497-502, 2000

4. Frizzera G. Immunosuppression, autoimmunity, and lymphoproliferative disorders. Hum Pathol 25:627-629, 1994

5. Kamel OW , van de Rijn M , Lebrun DP , Weiss LM , Warnke RA , Dorfman RF . Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: Frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 25:638-643, 1994

6. Kamel OW . latrogenic lymphoproliferative disorders in nontransplantation settings. Semin Diag Pathol 14:27-34, 1997

7. Kamel OW , Weiss LM , van de Rijin M , Colvy TV , Kingma DW , Jaffe ES . Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy, Am J Surg Pathol 20:1279-1287, 1996

8. loachim HL . Lymph node pathology, 3rd ed. JB Lippincott, Philadelphia, pp. 261-263, 2003

9. Banks PM , Witrak GA , Conn DL . Lymphoid neoplasia following connective tissue disease. Mayo Clin Proc 54:104-108, 1979

10.

10. Symmons DPM , Ahern M , Bacon PA , Hawkins CF , Amlot PL , Jones EL , Prior P , Scott DL . Lymphoproliferative malignancy in rheumatoid arthritis: A study of 20 cases. Ann Rheum Dis 43:132-135, 1984

11.

11. Kojima M , Nakamura S , Futamura N , Kurabayashi Y , Ban S , Itoh H , Yoshida K , Joshita T , Suchi T. Malignant lymphoma in patients with rheumatic disease other than Sjogren's syndrome: A clinicopathologic study of five cases and a review of the Japanese literature. Jpn J Clin Oncol 27:84-90, 1997

12.

12. Hoshida Y , Tomita Y , Zhiming D , Yamauchi A , Nakatsuka S-I , Kurasono Y , Arima Y , Tsudo M , Shintaku M , Aozasa K. Lymphoproliferative disorders in autoimmune disease in Japan: Analysis of clinicopathologic features and Epstein-Barr virus infection. Int J Cancer 108:443-449, 2004

13.

13. Green JA , Dawson AA , Walker W. Systemic lupus erythematosus and lymphoma. Lancet ii:753-756, 1978

14.

14. Kaplan EL , Meier P. Nonparametric estimation from incomplete observation. Am J Stat Assoc 53:457-481, 1958

15.

15. Peto PE , Pike MC , Armitage P , Breslow NE , Cox DR , Howard SV , Mantle N , McPherson K , Peto J , Smith G. Design and analysis of randomized clinical trails requiring prolonged observation of each patient. Br J Cancer 35:1-39, 1977

16.

16. Arnett FC , Edworthy SM , Bloch DA , McShane DJ , Fries JF , Cooper NS , Healey LA , Kaplan SR , Liang MH , Luthra HS , Medsger TA Jr , Mitchell DM , Neustadt DH , Pinals RS , Schaller JG , Sharp JT , Wilder RL , Hunder GG . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988

17.

17. Kumar V , Cotran RS , Robbins SL . Basic pathology, 7th ed, W.B. Saunders, Philadelphia, pp. 103-164, 2003

18.

18. Subcommittee for scleroderma criteria of the American Rheumatism Association diagnostic and therapeutic criteria committee . Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590, 1980

19.

19. Bohan A , Peter JB . Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344-347, 1975

20.

20. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In Jaffe ES , Harris NL , Stein H , Vardiman JW (eds). IARCPress, Lyon, 2001

21.

21. Lymphoma Study Group of Japanese Pathologists . The World Health Organization classification of malignant lymphoma in Japan: Incidence of recently recognized entities. Pathol Int 50:696-702, 2000

22.

22. Hans CP , Weisenburger DD , Greiner TC , Gascoyne RD , Delabie J , Ott G , Muller-Hermelink HK , Campo E , Braziel RM , Jaffe ES , Pan Z , Farinha P , Smith LM , Falini B , Banham AH , Rossenwald A , Staudt LM , Connors JM , Armitage JO , Chan WC . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004

23.

23. Kojima M , Motoori T , Itoh H , Shimizu K , lijima M , Tamaki Y , Murayama K , Ohno Y , Yoshida K , Masawa N , Nakamura S. Distribution of Epstein-Barr virus in systemic rheumatic disease (rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis) associated lymphadenopathy. A study of 49 cases. Int J Surg Pathol 13:2005 (in press)

24.

24. Beacklund E , Sundstrom C , Ekbon A , Catrina Al , Biberfeld P , Feltelius N , Klareskog L. Lymphoma subtypes in patients with rheumatoid arthritis. Increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 48:1543-1550, 2003

25.

25. Allzadeh AA , Elsen MB , Davis RE , Ma C , Lossos IS , Rosenwald A , Boldrick JC , Sabet H , Tran T , Yu X , Powell JI , Yang L , Marti GE , Moore T , Hudson J Jr , Lu L , Lewis DB , Tlbshfrani R , Sherlock G , Chan WC , Grelner TC , Weisenburger DD , Armitage JO , Warnke R , Levy R , Wilson W , Grever MR , Byrd JC , Botstein D , Brown P , Staudt LM . Distinct type of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 40:3503-3511, 2000

26.

26. Plater-Zyberk C , Maini RN , Lam K , Kennedy TD , Janossy G. A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytoc leukemia. Arthrits Rheum 28:971-976, 1985

27.

27. Dauphinee , Tovar Z , Talal N. B cells expressing CD5 are increased in Sjogren's syndrome. Arthritis Rheum 31:642-647, 1988

28.

28. Kamel OW , Holly EA , van de Rijin M , Lele C , Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 29:1676-1680, 1999